PurposeAn AAV genome that ubiquitously expresses tTA from the CAG promoter
|Item||Catalog #||Description||Quantity||Price (USD)|
|Plasmid||99118||Standard format: Plasmid sent in bacteria as agar stab||1||$75|
This material is available to academics and nonprofits only.
Vector typeMammalian Expression, AAV
Growth in Bacteria
Growth Strain(s)NEB Stable
Copy numberHigh Copy
Insert Size (bp)3332
- Promoter CAG
- Cloning method Restriction Enzyme
- 5′ cloning site KpnI (not destroyed)
- 3′ cloning site EcoRI/HindIII (not destroyed)
*Note: The tTA in this plasmid was made from a reverse tetracycline transactivator (rtTA) by changing two amino acids (G19E and P56A). These two residue changes have been shown to be sufficient for the reverse phenotype (10.1073/pnas.130192197).
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
For your Materials & Methods section:pAAV-CAG-tTA was a gift from Viviana Gradinaru (Addgene plasmid # 99118 ; http://n2t.net/addgene:99118 ; RRID:Addgene_99118)
For your References section:Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu WL, Sanchez-Guardado L, Lois C, Mazmanian SK, Deverman BE, Gradinaru V. Nat Neurosci. 2017 Aug;20(8):1172-1179. doi: 10.1038/nn.4593. Epub 2017 Jun 26. 10.1038/nn.4593 PubMed 28671695